{"id":"W2139004759","doi":"10.1093/neuonc/nou160","title":"Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma","year":2014,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; CancerCare Manitoba; Centre Hospitalier Universitaire de Sherbrooke; McGill University; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Temozolomide; Afatinib; Medicine; Internal medicine; Rash; Dacarbazine; Phases of clinical research; Oncology; Clinical endpoint; Adverse effect; Pharmacokinetics; Epidermal growth factor receptor; Pharmacology; Randomized controlled trial; Clinical trial; Chemotherapy; Erlotinib; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001712818,0.001534506,0.003261116,0.0003537705,0.0004111638,0.0008898854,0.001065504,0.001326734,0.004889394],"category_scores_gemma":[0.001317231,0.0006072911,0.001334962,0.0004870614,0.0009027812,0.001202746,0.000382809,0.003621844,0.000927921],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001134159,"about_ca_system_score_gemma":0.002112597,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001238363,"about_ca_topic_score_gemma":0.004134021,"domain_scores_codex":[0.9994801,0.0002099693,0.00004685996,0.0001225952,0.00004406907,0.00009648677],"domain_scores_gemma":[0.9990485,0.0001250757,0.0002358393,0.00005039327,0.00006840091,0.0004717971],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9223558,0.01705493,0.001795952,0.0009360348,0.001536667,0.0001276445,0.0001502026,0.0007487889,0.01142808,0.00015184,0.002888518,0.04082556],"study_design_scores_gemma":[0.8619472,0.1324153,0.002796612,0.0000277448,0.0004378768,0.0001215926,0.00002622615,0.0003863259,0.0007171786,0.0001297005,0.0009788488,0.00001535604],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9862023,0.004877091,0.0007178466,0.0009380896,0.0003165571,0.004209188,0.001107704,0.0001709936,0.001460211],"genre_scores_gemma":[0.9832829,0.003373971,0.00229228,0.001571335,0.0002650962,0.005586179,0.001628198,0.00003807443,0.001961922],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004889394,"threshold_uncertainty_score":0.01635665,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02280740465076383,"score_gpt":0.3333385568777372,"score_spread":0.3105311522269734,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}